ASCO GU 2018: Impact of metastatic local treatment in the strategy of metastatic renal cell carcinoma including stereotactic radiotherapy, surgery, and radio-frequency in an Expert Centre.

Standard of care for patients with metastatic renal cell carcinoma (mRCC) remains systemic therapy with targeted therapy and cyto-reductive nephrectomy, though even the nephrectomy has been called into question in the era of targeted therapy. However, targeted therapy, while they have drastically changed the management of mRCC, are associated with significant adverse effects. Naturally, these may result in compromised quality of life in sometimes very young, otherwise healthy patients.